The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control

Documenti analoghi

• Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
  di: Aronson, Ronnie, et al.
  Pubblicazione: (2018)
• A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
  di: Frias, Juan P., et al.
  Pubblicazione: (2018)
• Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone
  di: Trujillo, Jennifer M., et al.
  Pubblicazione: (2018)
• Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study)
  di: Yamada, Yuichiro, et al.
  Pubblicazione: (2017)
• Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
  di: Kovatchev, Boris, et al.
  Pubblicazione: (2020)